AACP
FOLD

Advantage Alpha Capital Partners’s Amicus Therapeutics FOLD Stock Holding History

Advantage Alpha Capital Partners’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-35,082
Closed -$201K – 135
2025
Q2 		$201K Buy
+35,082
New +$226K 0.05% 119

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Advantage Alpha Capital Partners's FOLD Position: Q3 2025 in Review

Advantage Alpha Capital Partners sold out of Amicus Therapeutics (FOLD) in Q3 2025, closing a stake of 35,082 shares — an estimated $201K sold.

Advantage Alpha Capital Partners first reported a position in FOLD in Q2 2025 and held it in 1 quarter. The position peaked at $201K in Q2 2025. 287 funds tracked by Wall St. Rank hold FOLD as of Q3 2025.

  • Advantage Alpha Capital Partners reported no remaining Amicus Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Advantage Alpha Capital Partners sold 35,082 Amicus Therapeutics shares in Q3 2025, an estimated $201K.
  • Advantage Alpha Capital Partners first reported a position in Amicus Therapeutics in Q2 2025 and held it in 1 quarter.
  • Advantage Alpha Capital Partners's Amicus Therapeutics position peaked at $201K in Q2 2025.
  • 287 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2025.

Based on Advantage Alpha Capital Partners's 13F filing for Q3 2025, filed 12 Nov 2025.